FNY Investment Advisers’s CRISPR Therapeutics CRSP Stock Holding History

FNY Investment Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+10	New	+$527	﹤0.01%	895
2025 Q1	–	Sell	-10,500	Closed	-$413K	–	765
2024 Q4	$413K	Buy	+10,500	New	+$496K	0.21%	95
2022 Q2	–	Sell	-15	Closed	–	–	737
2022 Q1	$0	Sell	15 -2,505	-99%	-$157K	﹤0.01%	770
2021 Q4	$190K	Buy	+2,520	New	+$220K	0.1%	165
2021 Q2	–	Sell	-20	Closed	-$2K	–	815
2021 Q1	$2K	Buy	+20	New	+$3.02K	﹤0.01%	692

Other funds holding CRSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

FNY Investment Advisers's CRSP Position: Q2 2026 in Review

FNY Investment Advisers opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 10 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #895 among its holdings. This is a return to the name: FNY Investment Advisers previously reported a position in CRSP as recently as Q4 2024.

FNY Investment Advisers first reported a position in CRSP in Q1 2021 and has held it in 5 quarters since. The position peaked at $413K in Q4 2024. 304 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

FNY Investment Advisers held 10 shares of CRISPR Therapeutics worth $0 as of Q2 2026.
CRISPR Therapeutics was a new FNY Investment Advisers position in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #895 holding.
FNY Investment Advisers first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 5 quarters since.
FNY Investment Advisers's CRISPR Therapeutics position peaked at $413K in Q4 2024.
304 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.